Authors' reply

V Furer^{1

2}, D Zisman³, E Pokroy-Shapira⁴, Y Molad^{2

4}, O Elkayam^{1

2}, D Paran^{1

2}

Affiliations

¹ a Department of Rheumatology , Tel Aviv Sourasky Medical Center , Tel Aviv , Israel.
² b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
³ c Rheumatology Unit Carmel Medical Center, Rappoport Faculty of Medicine , Haifa , Israel.
⁴ d Rheumatology Unit , Rabin Medical Center, Beilinson Hospital , Petach Tikva , Israel.

Comment

V Furer et al. Scand J Rheumatol. 2017 May.

. 2017 May;46(3):251-252.

doi: 10.1080/03009742.2016.1264628. Epub 2017 Feb 16.

V Furer^{1

2}, D Zisman³, E Pokroy-Shapira⁴, Y Molad^{2

4}, O Elkayam^{1

2}, D Paran^{1

2}

¹ a Department of Rheumatology , Tel Aviv Sourasky Medical Center , Tel Aviv , Israel.
² b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
³ c Rheumatology Unit Carmel Medical Center, Rappoport Faculty of Medicine , Haifa , Israel.
⁴ d Rheumatology Unit , Rabin Medical Center, Beilinson Hospital , Petach Tikva , Israel.

No abstract available

Comment on

Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al.
Carbajal S, Zamora-Martínez C, Prieto-González S, Quintana LF, Espinosa G, Cervera R. Carbajal S, et al. Scand J Rheumatol. 2017 May;46(3):250-251. doi: 10.1080/03009742.2016.1264626. Epub 2017 Feb 16. Scand J Rheumatol. 2017. PMID: 28276955 No abstract available.